Republican Congressman Missing For Weeks Sparks Concern And Speculation
This decision originates from the FDA, and the process there is trusted. However, claims that every panel unanimously voted against the drug due to ineffectiveness are disputed by oncologists. These experts highlight that an initial panel actually approved the drug, and further, that patients in the trial received immunotherapy, not chemotherapy as asserted by others. A researcher involved in the study expressed strong confidence in the drug’s positive results, seeing it as a much-needed alternative for patients with limited treatment options.
John Q. Hosedrinker